 | Up a level |
Qin, Shukui and Chen, Zhendong and Fang, Weijia and Ren, Zhenggang and Xu, Ruocai and Ryoo, Baek-Yeol and Meng, Zhiqiang and Bai, Yuxian and Chen, Xiaoming and Liu, Xiufeng and Xiao, Juxiang and Ho, Gwo Fuang and Mao, Yimin and Wang, Xin and Ying, Jieer and Li, Jianfeng and Zhong, Wenyan and Zhou, Yu and Siegel, Abby B. and Hao, Chunyi (2023) Pembrolizumab Versus Placebo as second-line therapy in patients From Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial. Journal of Clinical Oncology, 41 (7). 1434+. ISSN 0732-183X, DOI https://doi.org/10.1200/JCO.22.00620.
Chung, Hyun Cheol and Kang, Yoon-Koo and Chen, Zhendong and Bai, Yuxian and Ishak, Wan Zamaniah Wan and Shim, Byoung Yong and Park, Young Lee and Koo, Dong-Hoe and Lu, Jianwei and Xu, Jianming and Chon, Hong Jae and Bai, Li-Yuan and Zeng, Shan and Yuan, Ying and Chen, Yen-Yang and Gu, Kangsheng and Zhong, Wen Yan and Kuang, Shu and Shih, Chie-Schin and Qin, Shu-Kui (2022) Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer, 128 (5). pp. 995-1003. ISSN 0008-543X, DOI https://doi.org/10.1002/cncr.34019.
